Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $150 to $140.
Wells Fargo Maintains Overweight on Abbott Laboratories, Lowers Price Target to $140
Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $150 to $140.
Related Posts
You Can Have Any Color Tesla Model X To Qualify For EV Tax Credit — As Long As It Is Stealth Grey
While stealth grey is included in the base price, other colors like pearl white, deep blue metallic, solid black, and Ultra-red now come at an additional cost ranging from $1,500 to $2,500.
General Dynamics Bags $218M Contract To Expand Artillery Production
General Dynamics Corporation (NYSE: GD) business unit, General Dynamics Ordnance and Tactical Systems (OTS), won an initial task contract worth $218 million for
GrafTech Stock Slips On Q2 Revenue Miss, Warning On Challenging Operating Environment
GrafTech International Ltd (NYSE:EAF) reported second-quarter sales growth of 9.9% year-over-year to $363.65 million, missing the consensus of $368.3 million.…